Farxiga Insurance Denied? How to Appeal Your Dapagliflozin Denial

Farxiga (dapagliflozin) is an SGLT2 inhibitor with FDA-approved indications for type 2 diabetes, heart failure (HFrEF and HFpEF), and chronic kidney disease. It is recommended in major cardiology, nephrology, and endocrinology guidelines as a cornerstone therapy for patients with these overlapping conditions. Despite this strong clinical standing, insurance companies regularly deny Farxiga — sometimes favoring a competing SGLT2 inhibitor, sometimes demanding step therapy first. Here's how to appeal.

What Farxiga Treats and Why Patients Need It

Farxiga has three distinct FDA-approved indications:

1. Type 2 diabetes: Improves glycemic control and reduces cardiovascular events
2. Heart failure (HFrEF and HFpEF): Reduces hospitalization and cardiovascular death regardless of diabetes status
3. Chronic kidney disease (CKD): Slows progression of CKD and reduces renal and cardiovascular outcomes

Farxiga is notably one of the first medications approved to treat heart failure with preserved ejection fraction (HFpEF) — a condition with very few effective treatment options. For patients with this condition, Farxiga isn't a preference; it may be one of the only evidence-based pharmacological options available.

Common Denial Reasons for Farxiga

Step therapy / Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization: Nearly all plans require prior authorization for Farxiga. Step therapy protocols typically require metformin first for diabetes, and sometimes another agent before an SGLT2 inhibitor is approved.

Non-preferred formulary status: Some plans prefer Jardiance (empagliflozin) over Farxiga, denying coverage and directing patients to the preferred SGLT2 inhibitor instead.

Non-diabetes indication not covered: Plans with narrow diabetes drug coverage may deny Farxiga prescribed for heart failure or CKD if the claim is filed under those indications without diabetes as a primary diagnosis.

"Not medically necessary" for HFpEF: Given that HFpEF has traditionally had few treatment options, some insurers may try to argue insufficiency of evidence — despite FDA approval and major trial data supporting Farxiga for this indication.

Formulary exclusion: Particularly in government-sponsored plans, Farxiga may not be on the formulary at all.

Step-by-Step: How to Appeal a Farxiga Denial

Step 1: Identify the exact denial reason. The strategy differs whether you're fighting a step therapy denial, a formulary exclusion, or a non-covered indication.

Step 2: Confirm all diagnoses are correctly coded. Ensure ICD-10 codes for type 2 diabetes, heart failure (I50.20–I50.9), or CKD (N18.1–N18.9) are included in the claim. Missing diagnosis codes are a common reason for automatic denial.

Step 3: Obtain a comprehensive Letter of Medical Necessity. Your doctor — ideally the specialist prescribing Farxiga — should document the specific indication, prior treatments tried and failed, and clinical markers (eGFR, UACR, BNP, ejection fraction) supporting the need for dapagliflozin specifically.

Step 4: Gather supporting lab and clinical documentation. Prior labs, echocardiogram results, nephrology notes, and cardiology notes all strengthen your case.

Step 5: File the internal appeal. Submit within the deadline. If the plan denies on the basis that Jardiance is the preferred SGLT2 inhibitor, have your doctor explain the clinical reason for selecting dapagliflozin (e.g., specific trial evidence, HFpEF indication, patient tolerance, or established response).

Step 6: Request a peer-to-peer review. Particularly effective when a specialist like a nephrologist or cardiologist makes the call.

Step 7: Escalate to external appeal if necessary.

What to Include in Your Farxiga Appeal Letter

• Policy number, member ID, date of service, and claim reference
• Specific FDA-approved indication(s) for which Farxiga is prescribed
• Letter of Medical Necessity with clinical rationale
• Relevant labs: eGFR, UACR, HbA1c, BNP/NT-proBNP, ejection fraction
• Records of prior treatment history and outcomes
• Citation of DAPA-HF, DELIVER, and DAPA-CKD trial data as applicable
• ACC/AHA heart failure guideline citations (Class I recommendation for SGLT2 inhibitors)
• KDIGO guideline citations for CKD indication
• If plan prefers a different SGLT2: documented clinical reason for dapagliflozin specifically

Success Tips for Farxiga Appeals

Lead with the indication that's hardest to deny. If you have HFpEF, lean into the DELIVER trial and FDA approval — Farxiga is the most well-studied agent for HFpEF. This is a distinct clinical argument that's difficult for an insurer to dismiss.

Use specialist authority. A denial letter from a cardiologist or nephrologist's office carries far more weight than a primary care appeal for a drug prescribed outside their specialty.

If denied in favor of Jardiance, ask for a clinical exception. Request your doctor document why the therapeutic switch is clinically inappropriate — this is particularly relevant if you've been stable on dapagliflozin and switching would risk clinical disruption.

File quickly. Appeal deadlines can be as short as 30 days. Don't delay gathering documentation.

Know your external appeal rights. Under federal law (ERISA for employer plans, ACA for marketplace plans), you have the right to an independent External Independent Review: Complete Guide" class="auto-link">external review if your internal appeal fails.

Fight Back With ClaimBack

Insurance companies deny Farxiga every day — even for FDA-approved, guideline-recommended uses. ClaimBack helps you build a compelling case to get the medication your doctor determined you need.

Start your Farxiga appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeals
• Common Reasons Insurance Claims Are Denied